Pharma BD Deal Intelligence
A $10.5B stock-for-stock acquisition that gave J&J the OROS controlled-release platform behind Concerta and Ditropan XL, but the drug-delivery technology only ever enhanced existing Janssen products rather than delivering transformative new pipeline value.
Drug delivery platform added incremental value but never justified $10.5B price tag
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Banc of America's Jerry Treppel noted ALZA's high margin, high-growth revenues from Ditropan XL, Concerta, and Doxil would complement J&J's existing…
J&J bagged drug delivery maker ALZA for $12.3B, but the stock-for-stock deal was expected to be dilutive to EPS in 2001 and 2002, with accretion only from…
J&J's merger with ALZA combined the world's most diversified healthcare company with the premier drug delivery technology platform, expected to accelerate…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Johnson & Johnson merged with ALZA Corporation in a $10.5 billion stock-for-stock transaction (0.49 J&J shares per ALZA share), acquiring a leader in controlled-release and transdermal drug delivery technologies to enhance its Janssen Pharmaceuticals unit.
$3.5B Global Drug Delivery Market (2001)
ALZA Corporation pioneered osmotic and transdermal drug delivery systems. Their OROS technology enabled once-daily dosing of existing molecules, creating billions in value through improved patient compliance. At acquisition, ALZA's technologies were embedded in over 30 marketed products across multiple therapeutic areas.
J&J's $10.5B acquisition gave it control of OROS (osmotic delivery) and D-TRANS (transdermal) platforms. Concerta (OROS methylphenidate) for ADHD and Ditropan XL (oxybutynin) for overactive bladder were immediate revenue generators. The platform approach enabled J&J to reformulate existing drugs across its Janssen portfolio.
Johnson & Johnson closes acquisition/merger of ALZA Corporation for $10.5B, establishing strategic position and initiating integration.
J&J acquired ALZA for $10.5B gaining OROS drug delivery technology that enhanced existing products but never delivered transformative pipeline value.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / ALZA Corporation (this deal) | 2001 | $10.5B | 70 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2001 deals · Johnson & Johnson deals · Oncology deals